1 completed, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow BCR-ABL1 Fusion Protein Expression: new trials by email Literature Review of BCR-ABL1 Fusion Protein Expression trials Research Report on BCR-ABL1 Fusion Protein Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Blinatumomab, Cytarabine, Methotrexate - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 90 | 2017-11-29 | 2026-05-20 |
| Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. Cyclophosphamide, Cytarabine, Dasatinib - Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression | Phase 2 | Completed | M.D. Anderson Cancer Center | 107 | 2006-09-28 | 2025-02-17 |
Blast Crisis (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Myeloid, Accelerated Phase (1)
Bone Marrow Diseases (2) · Carcinogenesis (2) · Cell Transformation, Neoplastic (2) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2)
Cytarabine (2) · Methotrexate (2) · merphos (2) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Dasatinib (1) · Dexamethasone (1) · Doxorubicin (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1) · Prednisone (1) · Vincristine (1) · auricularum (1) · blinatumomab (1) · deltacortene (1) · dexamethasone 21-phosphate (1)
M.D. Anderson Cancer Center (2)
United States (2)
Elias Jabbour (1) · Farhad Ravandi-Kashani, MD (1)